{"id":351224,"date":"2025-08-25T20:41:10","date_gmt":"2025-08-25T20:41:10","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-syndax-pharmaceuticals\/"},"modified":"2025-08-25T20:41:10","modified_gmt":"2025-08-25T20:41:10","slug":"how-to-buy-syndax-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","title":{"rendered":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-351224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Syndax Pharmaceuticals, Inc. (SNDX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve %986 gelir art\u0131\u015f\u0131 ve FDA \u00d6ncelikli \u0130nceleme stat\u00fcs\u00fcne sahip bu umut vadeden biyoteknoloji hissesinde yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Syndax Pharmaceuticals, Inc. (SNDX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin ve %986 gelir art\u0131\u015f\u0131 ve FDA \u00d6ncelikli \u0130nceleme stat\u00fcs\u00fcne sahip bu umut vadeden biyoteknoloji hissesinde yat\u0131r\u0131m f\u0131rsatlar\u0131n\u0131 ke\u015ffedin."},"intro":"Yak\u0131n zamanda %986 gelir art\u0131\u015f\u0131 bildiren ve \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisi i\u00e7in FDA \u00d6ncelikli \u0130nceleme alan bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Syndax Pharmaceuticals, bilimsel at\u0131l\u0131mlar\u0131n ola\u011fan\u00fcst\u00fc getirilerle sonu\u00e7lanabilece\u011fi biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n patlay\u0131c\u0131 potansiyelini temsil ediyor. Bu sadece hisse senedi almakla ilgili de\u011fil; hayatlar\u0131 ve portf\u00f6yleri de\u011fi\u015ftirebilecek t\u0131bbi yenili\u011fe yat\u0131r\u0131m yapmakla ilgili.","intro_source":{"label":"Intro","type":"text","formatted_value":"Yak\u0131n zamanda %986 gelir art\u0131\u015f\u0131 bildiren ve \u00e7\u0131\u011f\u0131r a\u00e7an kanser tedavisi i\u00e7in FDA \u00d6ncelikli \u0130nceleme alan bir \u015firketin bir par\u00e7as\u0131na sahip oldu\u011funuzu hayal edin. Syndax Pharmaceuticals, bilimsel at\u0131l\u0131mlar\u0131n ola\u011fan\u00fcst\u00fc getirilerle sonu\u00e7lanabilece\u011fi biyoteknoloji yat\u0131r\u0131mlar\u0131n\u0131n patlay\u0131c\u0131 potansiyelini temsil ediyor. Bu sadece hisse senedi almakla ilgili de\u011fil; hayatlar\u0131 ve portf\u00f6yleri de\u011fi\u015ftirebilecek t\u0131bbi yenili\u011fe yat\u0131r\u0131m yapmakla ilgili."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Anl\u0131k F\u0131rsatlar<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Syndax Pharmaceuticals (SNDX) hisseleri <strong>15,74 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Ancak bu an\u0131 \u00f6zellikle heyecanl\u0131 k\u0131lan \u015fey \u015fudur: \u015firketin bir sonraki kazan\u00e7 a\u00e7\u0131klama tarihi olan <strong>4 Kas\u0131m 2025<\/strong> tarihini takviminize i\u015faretleyin.<\/p> <h3>4 Kas\u0131m Neden \u00d6nemli:<\/h3> <p>Son tarihsel verilere g\u00f6re, Syndax'\u0131n kazan\u00e7 raporlar\u0131 tam anlam\u0131yla oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirdi. 4 A\u011fustos'ta a\u00e7\u0131klanan 2025 2. \u00e7eyrek raporu, %986 y\u0131ll\u0131k gelir art\u0131\u015f\u0131 ile beklentileri a\u015farak tek g\u00fcnde %15,8'lik b\u00fcy\u00fck bir s\u0131\u00e7rama yaratt\u0131. Desen a\u00e7\u0131k: Syndax rapor verdi\u011finde piyasa dinliyor ve dramatik \u015fekilde tepki veriyor.<\/p> <h3>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/h3> <ul> <li>4 A\u011fustos 2025: Kazan\u00e7 sonras\u0131 %15,8 art\u0131\u015f (%986 gelir art\u0131\u015f\u0131 s\u00fcrprizi)<\/li> <li>May\u0131s 2025: EHA Kongresi'nde olumlu klinik veriler kurumsal al\u0131mlar\u0131 tetikledi<\/li> <li>\u015eubat 2025: Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar taraf\u0131ndan istikrarl\u0131 birikim<\/li> <\/ul> <p>Trend, olumlu klinik ve finansal haberlerin an\u0131nda ve \u00f6nemli fiyat hareketleri yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor. T\u00fcccarlar i\u00e7in bu kataliz\u00f6rlerden \u00f6nce pozisyon almak son derece kazan\u00e7l\u0131 olabilir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Patlamaya<\/h2> <p>Syndax hisseleri, biyoteknoloji volatilitesini m\u00fckemmel \u015fekilde yans\u0131tan duygusal bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131:<\/p> <ul> <li><strong>Ocak-Mart 2025:<\/strong> 9-11 $ aral\u0131\u011f\u0131nda konsolidasyon<\/li> <li><strong>Nisan-Haziran 2025:<\/strong> Kurumsal birikimle 13-14 $ aral\u0131\u011f\u0131na kademeli t\u0131rman\u0131\u015f<\/li> <li><strong>Temmuz 2025:<\/strong> K\u0131sa s\u00fcreli 9,87 $ geri \u00e7ekilme (geriye d\u00f6n\u00fcp bak\u0131ld\u0131\u011f\u0131nda m\u00fckemmel al\u0131m f\u0131rsat\u0131)<\/li> <li><strong>A\u011fustos 2025:<\/strong> Muhte\u015fem kazan\u00e7larla 15,74 $ ve \u00fczeri patlama<\/li> <\/ul> <p>6 ayl\u0131k grafik, b\u00fcy\u00fck haberler gelmeden \u00f6nce ak\u0131ll\u0131 paran\u0131n pozisyon olu\u015fturdu\u011fu klasik \"birikim-patlama\" modelini g\u00f6steriyor. Temmuz diplerinden yakla\u015f\u0131k 9,87 $ seviyesinden \u015fu anki 15 $ \u00fczeri seviyelere, sadece haftalar i\u00e7inde <strong>%59 kazan\u00e7<\/strong> - biyoteknoloji yat\u0131r\u0131m\u0131n\u0131 tan\u0131mlayan t\u00fcrden bir hareket.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu:<\/strong> 33-38 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %110-140 y\u00fckseli\u015f)<br> <em>Gerek\u00e7e: 25 Ekim FDA karar\u0131 + devam eden gelir ivmesi<\/em><\/li> <li><strong>2026 Tahmini:<\/strong> 45-55 $ aral\u0131\u011f\u0131<br> <em>Olas\u0131 kataliz\u00f6rler: Ek etiket geni\u015fletmeleri, uluslararas\u0131 onaylar<\/em><\/li> <li><strong>2028 Projeksiyonu:<\/strong> 60-75 $ aral\u0131\u011f\u0131<br> <em>Ba\u015far\u0131l\u0131 ticarile\u015fme ve \u00fcr\u00fcn hatt\u0131 geli\u015fimi varsay\u0131m\u0131<\/em><\/li> <li><strong>2030 Vizyonu:<\/strong> 80-100+ $ potansiyel<br> <em>Mevcut seyir devam ederse blockbuster ila\u00e7 stat\u00fcs\u00fc<\/em><\/li> <\/ul> <p><strong>Karar: G\u00dc\u00c7L\u00dc AL<\/strong> - Patlayan gelir, FDA kataliz\u00f6rleri ve makul de\u011ferleme nadir bir f\u0131rsat yarat\u0131yor.<\/p> <h2>\u26a0\ufe0f Riskleri Anlamak: Biyoteknoloji Ger\u00e7ekleri<\/h2> <p>Y\u00fckseli\u015f potansiyeli \u00e7ok b\u00fcy\u00fck olsa da, Syndax \u00f6nemli riskler ta\u015f\u0131yor ve her yat\u0131r\u0131mc\u0131n\u0131n bunlar\u0131 anlamas\u0131 gerekiyor:<\/p> <ul> <li><strong>Reg\u00fclasyon Riski:<\/strong> 25 Ekim FDA karar\u0131 her iki y\u00f6nde de olabilir<\/li> <li><strong>Klinik Deneme Riski:<\/strong> Gelecek \u00e7al\u0131\u015fmalar erken ba\u015far\u0131y\u0131 tekrarlamayabilir<\/li> <li><strong>Nakit Yak\u0131m\u0131:<\/strong> B\u00fcy\u00fcmeye ra\u011fmen \u015firket \u00f6nemli nakit harc\u0131yor<\/li> <li><strong>Volatilite:<\/strong> 52 haftal\u0131k aral\u0131k 8,58-22,50 $ aras\u0131nda a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131<\/li> <li><strong>\u00dcr\u00fcn Hatt\u0131 Konsantrasyonu:<\/strong> Revuforj ba\u015far\u0131s\u0131na a\u011f\u0131r ba\u011f\u0131ml\u0131l\u0131k<\/li> <\/ul> <p>Ancak mevcut 517,9 milyon $ nakit pozisyonu, hemen seyrelme riskini azaltarak yeterli finansal alan sa\u011fl\u0131yor.<\/p> <h2>\ud83d\ude80 Riskleri G\u00f6lgede B\u0131rakan Pozitif Sinyaller<\/h2> <p>Syndax i\u00e7in y\u00fckseli\u015f senaryosu ikna edici:<\/p> <ul> <li><strong>%986 Gelir Art\u0131\u015f\u0131:<\/strong> Yaz\u0131m hatas\u0131 de\u011fil\u20142025 2. \u00e7eyrek ger\u00e7ek performans<\/li> <li><strong>FDA \u00d6ncelikli \u0130nceleme:<\/strong> 25 Ekim geni\u015fletilmi\u015f onay karar\u0131 tarihi<\/li> <li><strong>Kurumsal Destek:<\/strong> B\u00fcy\u00fck fonlar pozisyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131r\u0131yor<\/li> <li><strong>\u0130lk Hareket Avantaj\u0131:<\/strong> Kan\u0131tlanm\u0131\u015f etkinli\u011fi olan tek menin inhibit\u00f6r\u00fc<\/li> <li><strong>Pazar Geni\u015flemesi:<\/strong> AML hastalar\u0131n\u0131n %5'inden %30'una potansiyel eri\u015fim art\u0131\u015f\u0131<\/li> <\/ul> <h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz miktarla ba\u015flay\u0131n\u2014biyoteknoloji y\u00fcksek risklidir<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>4 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun:<\/strong> Kazan\u00e7lar ba\u015fka b\u00fcy\u00fck bir kataliz\u00f6r olabilir<\/li> <li><strong>Ekim Ay\u0131 Putlar\u0131n\u0131 D\u00fc\u015f\u00fcn\u00fcn:<\/strong> FDA karar\u0131 riskine kar\u015f\u0131 koruma<\/li> <\/ol> <p>Ve benim favori t\u00fcccar \u00f6\u011f\u00fcd\u00fcm: \"Biyoteknoloji hissesi almak fl\u00f6rt etmek gibidir\u2014bazen \u00e7\u0131\u011f\u0131r a\u00e7an tedavi gelir, bazen yan etkiler. Ba\u011flanmadan \u00f6nce her zaman klinik verileri okuyun!\"<\/p> <h2>\u2705 Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Rahat bir miktarla ba\u015flay\u0131n\u2014100 $ bile yolculu\u011funuza ba\u015flaman\u0131z\u0131 sa\u011flar<\/td><\/tr> <tr><td>3<\/td><td>\"SNDX\" Aramas\u0131 Yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve \u0130\u015flemi Ger\u00e7ekle\u015ftirin<\/td><td>Sat\u0131n alma onay\u0131ndan \u00f6nce emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, SNDX gibi hisselerde i\u015flem yapmak i\u00e7in ola\u011fan\u00fcst\u00fc avantajlar sunuyor:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma:<\/strong> Sadece 5 $ ile ba\u015flay\u0131n\u2014stratejileri test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Sadece bir belge ile dakikalar i\u00e7inde KYC tamamlan\u0131r<\/li> <li><strong>\u00c7ekim Se\u00e7enekleri:<\/strong> Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce y\u00f6ntem<\/li> <li><strong>Kullan\u0131c\u0131 Dostu Platform:<\/strong> Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li> <\/ul> <p>D\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan biyoteknoloji f\u0131rsatlar\u0131na kat\u0131lmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option'u ideal k\u0131lar.<\/p> <h2>\ud83e\uddec Syndax 2025'te: Onkoloji Yenilik Lideri<\/h2> <p>Syndax Pharmaceuticals sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014kanser tedavisi inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. \u00d6nc\u00fc ila\u00e7lar\u0131 Revuforj\u00ae (revumenib), di\u011fer se\u00e7enekleri t\u00fckenmi\u015f akut l\u00f6semi hastalar\u0131nda ola\u011fan\u00fcst\u00fc sonu\u00e7lar g\u00f6steren s\u0131n\u0131f\u0131nda ilk menin inhibit\u00f6r\u00fcd\u00fcr.<\/p> <p>\u015eirketin mevcut piyasa konumu \u00f6zellikle g\u00fc\u00e7l\u00fc \u00e7\u00fcnk\u00fc saf Ar-Ge'den ticarile\u015fmeye ge\u00e7i\u015f yapt\u0131. Sadece Revuforj'dan 2025 2. \u00e7eyrekte 28,6 milyon $ gelir elde ederek \u00e7eyrekten \u00e7eyre\u011fe %43 art\u0131\u015f g\u00f6steriyor ve ger\u00e7ek ticari ivme sergiliyorlar.<\/p> <p><strong>2025'ten \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Syndax ara\u015ft\u0131rma ekibi, menin inhibit\u00f6r teknolojilerinin kanserin \u00f6tesinde uygulamalara sahip olabilece\u011fini ke\u015ffetti\u2014\u00f6n veriler belirli genetik bozukluklarda potansiyel g\u00f6steriyor ve milyarlarca dolar de\u011ferinde tamamen yeni pazar f\u0131rsatlar\u0131 a\u00e7\u0131yor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa Konumu ve Anl\u0131k F\u0131rsatlar<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Syndax Pharmaceuticals (SNDX) hisseleri <strong>15,74 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Ancak bu an\u0131 \u00f6zellikle heyecanl\u0131 k\u0131lan \u015fey \u015fudur: \u015firketin bir sonraki kazan\u00e7 a\u00e7\u0131klama tarihi olan <strong>4 Kas\u0131m 2025<\/strong> tarihini takviminize i\u015faretleyin.<\/p>\n<h3>4 Kas\u0131m Neden \u00d6nemli:<\/h3>\n<p>Son tarihsel verilere g\u00f6re, Syndax&#8217;\u0131n kazan\u00e7 raporlar\u0131 tam anlam\u0131yla oyunun kurallar\u0131n\u0131 de\u011fi\u015ftirdi. 4 A\u011fustos&#8217;ta a\u00e7\u0131klanan 2025 2. \u00e7eyrek raporu, %986 y\u0131ll\u0131k gelir art\u0131\u015f\u0131 ile beklentileri a\u015farak tek g\u00fcnde %15,8&#8217;lik b\u00fcy\u00fck bir s\u0131\u00e7rama yaratt\u0131. Desen a\u00e7\u0131k: Syndax rapor verdi\u011finde piyasa dinliyor ve dramatik \u015fekilde tepki veriyor.<\/p>\n<h3>Son Kazan\u00e7lar\u0131n Etki Analizi:<\/h3>\n<ul>\n<li>4 A\u011fustos 2025: Kazan\u00e7 sonras\u0131 %15,8 art\u0131\u015f (%986 gelir art\u0131\u015f\u0131 s\u00fcrprizi)<\/li>\n<li>May\u0131s 2025: EHA Kongresi&#8217;nde olumlu klinik veriler kurumsal al\u0131mlar\u0131 tetikledi<\/li>\n<li>\u015eubat 2025: Ak\u0131ll\u0131 yat\u0131r\u0131mc\u0131lar taraf\u0131ndan istikrarl\u0131 birikim<\/li>\n<\/ul>\n<p>Trend, olumlu klinik ve finansal haberlerin an\u0131nda ve \u00f6nemli fiyat hareketleri yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor. T\u00fcccarlar i\u00e7in bu kataliz\u00f6rlerden \u00f6nce pozisyon almak son derece kazan\u00e7l\u0131 olabilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Fiyat Yolculu\u011fu: M\u00fccadeleden Patlamaya<\/h2>\n<p>Syndax hisseleri, biyoteknoloji volatilitesini m\u00fckemmel \u015fekilde yans\u0131tan duygusal bir ini\u015f \u00e7\u0131k\u0131\u015f ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>Ocak-Mart 2025:<\/strong> 9-11 $ aral\u0131\u011f\u0131nda konsolidasyon<\/li>\n<li><strong>Nisan-Haziran 2025:<\/strong> Kurumsal birikimle 13-14 $ aral\u0131\u011f\u0131na kademeli t\u0131rman\u0131\u015f<\/li>\n<li><strong>Temmuz 2025:<\/strong> K\u0131sa s\u00fcreli 9,87 $ geri \u00e7ekilme (geriye d\u00f6n\u00fcp bak\u0131ld\u0131\u011f\u0131nda m\u00fckemmel al\u0131m f\u0131rsat\u0131)<\/li>\n<li><strong>A\u011fustos 2025:<\/strong> Muhte\u015fem kazan\u00e7larla 15,74 $ ve \u00fczeri patlama<\/li>\n<\/ul>\n<p>6 ayl\u0131k grafik, b\u00fcy\u00fck haberler gelmeden \u00f6nce ak\u0131ll\u0131 paran\u0131n pozisyon olu\u015fturdu\u011fu klasik &#8220;birikim-patlama&#8221; modelini g\u00f6steriyor. Temmuz diplerinden yakla\u015f\u0131k 9,87 $ seviyesinden \u015fu anki 15 $ \u00fczeri seviyelere, sadece haftalar i\u00e7inde <strong>%59 kazan\u00e7<\/strong> &#8211; biyoteknoloji yat\u0131r\u0131m\u0131n\u0131 tan\u0131mlayan t\u00fcrden bir hareket.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu:<\/strong> 33-38 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %110-140 y\u00fckseli\u015f)<br \/> <em>Gerek\u00e7e: 25 Ekim FDA karar\u0131 + devam eden gelir ivmesi<\/em><\/li>\n<li><strong>2026 Tahmini:<\/strong> 45-55 $ aral\u0131\u011f\u0131<br \/> <em>Olas\u0131 kataliz\u00f6rler: Ek etiket geni\u015fletmeleri, uluslararas\u0131 onaylar<\/em><\/li>\n<li><strong>2028 Projeksiyonu:<\/strong> 60-75 $ aral\u0131\u011f\u0131<br \/> <em>Ba\u015far\u0131l\u0131 ticarile\u015fme ve \u00fcr\u00fcn hatt\u0131 geli\u015fimi varsay\u0131m\u0131<\/em><\/li>\n<li><strong>2030 Vizyonu:<\/strong> 80-100+ $ potansiyel<br \/> <em>Mevcut seyir devam ederse blockbuster ila\u00e7 stat\u00fcs\u00fc<\/em><\/li>\n<\/ul>\n<p><strong>Karar: G\u00dc\u00c7L\u00dc AL<\/strong> &#8211; Patlayan gelir, FDA kataliz\u00f6rleri ve makul de\u011ferleme nadir bir f\u0131rsat yarat\u0131yor.<\/p>\n<h2>\u26a0\ufe0f Riskleri Anlamak: Biyoteknoloji Ger\u00e7ekleri<\/h2>\n<p>Y\u00fckseli\u015f potansiyeli \u00e7ok b\u00fcy\u00fck olsa da, Syndax \u00f6nemli riskler ta\u015f\u0131yor ve her yat\u0131r\u0131mc\u0131n\u0131n bunlar\u0131 anlamas\u0131 gerekiyor:<\/p>\n<ul>\n<li><strong>Reg\u00fclasyon Riski:<\/strong> 25 Ekim FDA karar\u0131 her iki y\u00f6nde de olabilir<\/li>\n<li><strong>Klinik Deneme Riski:<\/strong> Gelecek \u00e7al\u0131\u015fmalar erken ba\u015far\u0131y\u0131 tekrarlamayabilir<\/li>\n<li><strong>Nakit Yak\u0131m\u0131:<\/strong> B\u00fcy\u00fcmeye ra\u011fmen \u015firket \u00f6nemli nakit harc\u0131yor<\/li>\n<li><strong>Volatilite:<\/strong> 52 haftal\u0131k aral\u0131k 8,58-22,50 $ aras\u0131nda a\u015f\u0131r\u0131 fiyat dalgalanmalar\u0131<\/li>\n<li><strong>\u00dcr\u00fcn Hatt\u0131 Konsantrasyonu:<\/strong> Revuforj ba\u015far\u0131s\u0131na a\u011f\u0131r ba\u011f\u0131ml\u0131l\u0131k<\/li>\n<\/ul>\n<p>Ancak mevcut 517,9 milyon $ nakit pozisyonu, hemen seyrelme riskini azaltarak yeterli finansal alan sa\u011fl\u0131yor.<\/p>\n<h2>\ud83d\ude80 Riskleri G\u00f6lgede B\u0131rakan Pozitif Sinyaller<\/h2>\n<p>Syndax i\u00e7in y\u00fckseli\u015f senaryosu ikna edici:<\/p>\n<ul>\n<li><strong>%986 Gelir Art\u0131\u015f\u0131:<\/strong> Yaz\u0131m hatas\u0131 de\u011fil\u20142025 2. \u00e7eyrek ger\u00e7ek performans<\/li>\n<li><strong>FDA \u00d6ncelikli \u0130nceleme:<\/strong> 25 Ekim geni\u015fletilmi\u015f onay karar\u0131 tarihi<\/li>\n<li><strong>Kurumsal Destek:<\/strong> B\u00fcy\u00fck fonlar pozisyonlar\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131r\u0131yor<\/li>\n<li><strong>\u0130lk Hareket Avantaj\u0131:<\/strong> Kan\u0131tlanm\u0131\u015f etkinli\u011fi olan tek menin inhibit\u00f6r\u00fc<\/li>\n<li><strong>Pazar Geni\u015flemesi:<\/strong> AML hastalar\u0131n\u0131n %5&#8217;inden %30&#8217;una potansiyel eri\u015fim art\u0131\u015f\u0131<\/li>\n<\/ul>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n:<\/strong> Tamamen kaybetmeyi g\u00f6ze alabilece\u011finiz miktarla ba\u015flay\u0131n\u2014biyoteknoloji y\u00fcksek risklidir<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131:<\/strong> T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>4 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun:<\/strong> Kazan\u00e7lar ba\u015fka b\u00fcy\u00fck bir kataliz\u00f6r olabilir<\/li>\n<li><strong>Ekim Ay\u0131 Putlar\u0131n\u0131 D\u00fc\u015f\u00fcn\u00fcn:<\/strong> FDA karar\u0131 riskine kar\u015f\u0131 koruma<\/li>\n<\/ol>\n<p>Ve benim favori t\u00fcccar \u00f6\u011f\u00fcd\u00fcm: &#8220;Biyoteknoloji hissesi almak fl\u00f6rt etmek gibidir\u2014bazen \u00e7\u0131\u011f\u0131r a\u00e7an tedavi gelir, bazen yan etkiler. Ba\u011flanmadan \u00f6nce her zaman klinik verileri okuyun!&#8221;<\/p>\n<h2>\u2705 Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Rahat bir miktarla ba\u015flay\u0131n\u2014100 $ bile yolculu\u011funuza ba\u015flaman\u0131z\u0131 sa\u011flar<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;SNDX&#8221; Aramas\u0131 Yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in tam sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve \u0130\u015flemi Ger\u00e7ekle\u015ftirin<\/td>\n<td>Sat\u0131n alma onay\u0131ndan \u00f6nce emir detaylar\u0131n\u0131 iki kez kontrol edin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, SNDX gibi hisselerde i\u015flem yapmak i\u00e7in ola\u011fan\u00fcst\u00fc avantajlar sunuyor:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma:<\/strong> Sadece 5 $ ile ba\u015flay\u0131n\u2014stratejileri test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama:<\/strong> Sadece bir belge ile dakikalar i\u00e7inde KYC tamamlan\u0131r<\/li>\n<li><strong>\u00c7ekim Se\u00e7enekleri:<\/strong> Kripto, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil y\u00fczlerce y\u00f6ntem<\/li>\n<li><strong>Kullan\u0131c\u0131 Dostu Platform:<\/strong> Yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li>\n<\/ul>\n<p>D\u00fc\u015f\u00fck giri\u015f engeli, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan biyoteknoloji f\u0131rsatlar\u0131na kat\u0131lmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in Pocket Option&#8217;u ideal k\u0131lar.<\/p>\n<h2>\ud83e\uddec Syndax 2025&#8217;te: Onkoloji Yenilik Lideri<\/h2>\n<p>Syndax Pharmaceuticals sadece ba\u015fka bir biyoteknoloji \u015firketi de\u011fil\u2014kanser tedavisi inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. \u00d6nc\u00fc ila\u00e7lar\u0131 Revuforj\u00ae (revumenib), di\u011fer se\u00e7enekleri t\u00fckenmi\u015f akut l\u00f6semi hastalar\u0131nda ola\u011fan\u00fcst\u00fc sonu\u00e7lar g\u00f6steren s\u0131n\u0131f\u0131nda ilk menin inhibit\u00f6r\u00fcd\u00fcr.<\/p>\n<p>\u015eirketin mevcut piyasa konumu \u00f6zellikle g\u00fc\u00e7l\u00fc \u00e7\u00fcnk\u00fc saf Ar-Ge&#8217;den ticarile\u015fmeye ge\u00e7i\u015f yapt\u0131. Sadece Revuforj&#8217;dan 2025 2. \u00e7eyrekte 28,6 milyon $ gelir elde ederek \u00e7eyrekten \u00e7eyre\u011fe %43 art\u0131\u015f g\u00f6steriyor ve ger\u00e7ek ticari ivme sergiliyorlar.<\/p>\n<p><strong>2025&#8217;ten \u0130lgin\u00e7 Bir Ger\u00e7ek:<\/strong> Syndax ara\u015ft\u0131rma ekibi, menin inhibit\u00f6r teknolojilerinin kanserin \u00f6tesinde uygulamalara sahip olabilece\u011fini ke\u015ffetti\u2014\u00f6n veriler belirli genetik bozukluklarda potansiyel g\u00f6steriyor ve milyarlarca dolar de\u011ferinde tamamen yeni pazar f\u0131rsatlar\u0131 a\u00e7\u0131yor.<\/p>\n"},"faq":[{"question":"Syndax Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"SNDX\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"Syndax'\u0131n FDA \u00d6ncelikli \u0130nceleme durumu nedir?","answer":"Syndax, 25 Ekim 2025 tarihinde FDA'dan geni\u015fletilmi\u015f onay i\u00e7in \u00f6ncelikli inceleme alm\u0131\u015ft\u0131r."},{"question":"Syndax hisselerinin riskleri nelerdir?","answer":"Reg\u00fclasyon karar\u0131 riski, klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit yak\u0131m\u0131, y\u00fcksek volatilite ve \u00fcr\u00fcn hatt\u0131 konsantrasyonu ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Syndax hissesi al\u0131rken ne \u00f6nerilir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli tarihler i\u00e7in uyar\u0131 kurun ve risklere kar\u015f\u0131 put opsiyonlar\u0131 d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu \u00e7ekim se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Syndax Pharmaceuticals hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"SNDX\" sembol\u00fcn\u00fc aray\u0131n, limit emirleri kullanarak al\u0131m yap\u0131n ve i\u015flemi onaylay\u0131n."},{"question":"Syndax'\u0131n FDA \u00d6ncelikli \u0130nceleme durumu nedir?","answer":"Syndax, 25 Ekim 2025 tarihinde FDA'dan geni\u015fletilmi\u015f onay i\u00e7in \u00f6ncelikli inceleme alm\u0131\u015ft\u0131r."},{"question":"Syndax hisselerinin riskleri nelerdir?","answer":"Reg\u00fclasyon karar\u0131 riski, klinik deneme ba\u015far\u0131s\u0131zl\u0131\u011f\u0131, nakit yak\u0131m\u0131, y\u00fcksek volatilite ve \u00fcr\u00fcn hatt\u0131 konsantrasyonu ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar i\u00e7in Syndax hissesi al\u0131rken ne \u00f6nerilir?","answer":"K\u00fc\u00e7\u00fck ba\u015flay\u0131n, dolar maliyet ortalamas\u0131 yap\u0131n, \u00f6nemli tarihler i\u00e7in uyar\u0131 kurun ve risklere kar\u015f\u0131 put opsiyonlar\u0131 d\u00fc\u015f\u00fcn\u00fcn."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu \u00e7ekim se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T20:41:10+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T20:41:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\",\"name\":\"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-25T20:41:10+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","og_locale":"tr_TR","og_type":"article","og_title":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T20:41:10+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T20:41:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/","name":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-25T20:41:10+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Syndax Pharmaceuticals, Inc. (SNDX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Syndax Pharmaceuticals, Inc. (SNDX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":351225,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Syndax Pharmaceuticals, Inc. (SNDX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"},"pt_AA":{"locale":"pt_AA","id":351221,"slug":"how-to-buy-syndax-pharmaceuticals","post_title":"Como comprar a\u00e7\u00f5es da Syndax Pharmaceuticals, Inc. (SNDX) - Investimento em a\u00e7\u00f5es da Syndax Pharmaceuticals, Inc. (SNDX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-syndax-pharmaceuticals\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351224","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=351224"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/351224\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=351224"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=351224"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=351224"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}